A Study to Evaluate Once-Daily Oral VT-464 in Patients With Castration-Resistant Prostate Cancer

Completed · Phase 1/Phase 2

Conditions studied: Castration-resistant Prostate Cancer, CRPC

In brief

The goal of this clinical study is to determine the safety, tolerability, pharmacokinetics and activity of once-daily (QD) oral dosing of VT-464, a lyase-selective inhibitor of CYP17, in patients with castration-resistant prostate cancer (CRPC).

Key facts

Study ID

NCT02361086

Run by

Innocrin Pharmaceutical

People needed

21

Starts

2014-06-01

Expected to finish

2018-06-01

Last updated by the study team

2019-02-01

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

Where it is running

• H. Lee Moffitt Cancer Center and Research Institute — Tampa, Florida, United States
• Urology Cancer Center — Omaha, Nebraska, United States
• Duke University Medical Center — Durham, North Carolina, United States
• Carolina Urologic Research Center — Myrtle Beach, South Carolina, United States
• Virginia Oncology Associates — Norfolk, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.